Katsushima, K., Joshi, K., Yuan, M., Batish, M., Stapleton, S., Jallo, G., Seal, S., Taylor, M. D., Wechsler-Reya, R. J., Eberhart, C. G., & Perera, R. J. (2024). MDB-01. A POSITIVE FEEDBACK LOOP BETWEENLNC-HLX-2-7, HLX, AND MYC STRONGLY PROMOTES GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.450

Gao, L., Kaushik, D., Van Tine, B. A., Ingham, M. A., Attia, S., Meyer, C. F., Schwartz, G. K., Maliakal, P., Baird, J. D., Ma, J., Barrett, R., D’Silva, D., O’Keefe, K., & Kong, R. (2024). Pharmacokinetics of dacarbazine and unesbulin and CYP1A2‐mediated drug interactions in patients with leiomyosarcoma. Clinical and Translational Science, 17(2). Portico. https://doi.org/10.1111/cts.13709

Lale Ngema, S., Dookie, N., Perumal, R., Nandlal, L., Naicker, N., Peter Letsoalo, M., O’Donnell, M., Khan, A., Padayatchi, N., & Naidoo, K. (2023). Isoniazid resistance-conferring mutations are associated with highly variable phenotypic resistance. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 33, 100387. https://doi.org/10.1016/j.jctube.2023.100387

Kümpornsin, K., Kochakarn, T., Yeo, T., Okombo, J., Luth, M. R., Hoshizaki, J., Rawat, M., Pearson, R. D., Schindler, K. A., Mok, S., Park, H., Uhlemann, A.-C., Jana, G. P., Maity, B. C., Laleu, B., Chenu, E., Duffy, J., Moliner Cubel, S., Franco, V., … Lee, M. C. S. (2023). Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-38774-1

Schvartzman, J.-M., Forsyth, G., Walch, H., Chatila, W., Taglialatela, A., Lee, B. J., Zhu, X., Gershik, S., Cimino, F. V., Santella, A., Menghrajani, K., Ciccia, A., Koche, R., Sánchez-Vega, F., Zha, S., & Thompson, C. B. (2023). Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination. Molecular Cell, 83(13), 2347-2356.e8. https://doi.org/10.1016/j.molcel.2023.05.026

Herzberg, B. O., & Manji, G. A. (2023). KRAS: Druggable at Last. The Oncologist, 28(4), 283–286. https://doi.org/10.1093/oncolo/oyad014

Naqvi, S. A. A., Fatima, S., Asghar, N., Ijaz, H., Ayaz, A., He, H., Husnain, M., Chakraborty, R., Riaz, I., & Aljama, M. A. (2022). Post Autologous Stem Cell Transplant Maintenance in Patients with Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis. Blood, 140(Supplement 1), 10111–10113. https://doi.org/10.1182/blood-2022-170869

Macy, M., Cash, T., Pinto, N., Pressey, J. G., Szalontay, L., Furman, W. L., Bukowinski, A., Foster, J. H., Friedman, G. K., HaDuong, J., Fox, E., Weigel, B. J., Grevel, J., Huang, F., Phelps, C., Childs, B. H., Chung, J., Chaturvedi, S., Schulz, A., & DuBois, S. G. (2022). Phase I dose-escalation study of the pan-PI3 K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors. European Journal of Cancer, 174, S28–S29. https://doi.org/10.1016/s0959-8049(22)00878-4